RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Other Events
Item 8.01. Other Events.
On March 28, 2017, Ritter Pharmaceuticals, Inc. (the Company)
issued a press release announcing topline findings from the
Companys Phase 2b/3 study designed to evaluate RP-G28 in subjects
with lactose intolerance (the Press Release). A copy of the Press
Release is filed as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference.
On March 29, 2017, the Company held a conference call and webcast
to present the topline clinical trial results. A copy of the
slides presented during that call is filed as Exhibit 99.2 to
this Current Report on Form 8-K and is incorporated herein by
reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 |
Ritter Pharmaceuticals, Inc. press release dated March 28, 2017, entitled Ritter Pharmaceuticals Announces its Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial |
|
| 99.2 |
Slide Presentation for Investor Conference Call and Webcast on March 29, 2017 |
About RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR)
Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues. RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Recent Trading Information
RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) closed its last trading session down -0.32 at 1.63 with 332,493 shares trading hands.
